¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hearing level"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ, ÃÖ´ëÈ£±â°ª
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ, ÃÖ´ëÈí±â°ª
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • noise level
    ¼ÒÀ½¼öÁØ, ÀâÀ½µµ
  • no-observed-effect level
    ¹«°üÂûÈ¿°ú¼öÁØ
  • peak level
    ÃÖ°íÄ¡
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
  • saturation sound pressure level
    Æ÷È­¼Ò¸®¾Ð¼öÁØ, Æ÷È­À½¾Ð¼öÁØ
  • sound level meter
    1. À½·®¼öÁذè 2. ¼ÒÀ½°è
  • sound pressure level
    ¼Ò¸®¾Ð¼öÁØ, À½¾Ð¼öÁØ
  • speech interference level
    ¾ð¾î¹æÇØÄ¡, ´ëÈ­¹æÇØÄ¡
  • steady-state level
    Ç×Á¤»óżöÁØ
  • sedimentation level
    ħÀüÃþ
  • sensation level
    °¨°¢Ä¡, °¨À½Ä¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • level
    Æ÷È­¼Ò¸®¾Ð¼öÁØ
  • level of significance
    À¯ÀǼöÁØ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ
  • maximum permissible level
    ÃÖ´ëÇã¿ë¼öÁØ
  • maximum safe intensity level
    ÃÖ´ë¾ÈÀü°­µµ¼öÁØ
  • no-observed-effect level
    ¹«È¿°ú°üÂû¼öÁØ
  • noise level
    ¼ÒÀ½¼öÁØ, ÀâÀ½µµ
  • peak level
    ÃÖ°íÄ¡
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
  • saturation sound pressure level
    Æ÷È­À½¾Ð¼öÁØ,
  • sedimentation level
    ħÀüÃþ
  • sensation level
    °¨À½Ä¡, °¨°¢Ä¡
  • sensorineural acuity level
    °ñµµÃ»·ÂÁ¤¹Ð¿ªÄ¡
  • sound pressure level
    À½¾Ð¼öÁØ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • NIHL [=noise induced hearing loss]
    ¼ÒÀ½¼º ³­Ã»
  • absolute hearing
    Àý´ëÀ½°¨
  • functional hearing loss
    ±â´É(¼º) ³­Ã»
  • group hearing aid
    Áý´Üº¸Ã»±â
  • hearing =audition
    û·Â, û°¢
  • hearing =audition
    û°¢(ôéÊÆ), û·Â(ôéæ³)
  • hearing acuity
    û·Â
  • hearing aid
    º¸Ã»±â
  • hearing aid, electric
    Àü±âº¸Ã»±â
  • hearing aid, group
    Áý´Üº¸Ã»±â
  • hearing aid, transistor
    Æ®·£Áö½ºÅͺ¸Ã»±â
  • hearing defect
    û·ÂÀå¾Ö
  • hearing disorder
    û·ÂÀå¾Ö
  • hearing disturbance
    û·ÂÀå¾Ö
  • hearing function
    û°¢±â´É
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • effective perceived noise level =EPNDB
    ½ÇÈ¿°¨¼ö¼ÒÀ½(Ëà̷˧ËÛËÛËô)·¹ º§.
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁöÁØÀ§(¡­ñÞêÈ).
  • excess level
    °úÀ×¼öÁØ
  • fasting blood sugar (level) =FBS
    °øº¹½ÃÇ÷´ç(Ä¡).
  • fat blood level
    Áö¹æÇ÷ Ãþ
  • firing level
    ¹ßÈ­¼öÁØ.
  • fluid fluid level
    ¾×ü ¾×ü Ãþ
  • fluid level
    ¾×ü Ãþ
  • glucose level
    Æ÷µµ´çÄ¡<--ÁØÀ§>
  • ground water level
    ÁöÇϼö³ôÀÌ.
  • increased level
    Áõ°¡Ä¡
  • intensity level
    °­µµ¼öÁØ(Ë­öôâ©ñÞ).
  • level
    ´ë, ¼öÁØ
  • level gauge
    ¾×¸é°è(ËâËÎË­).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • window level
    â³ôÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
SAL sensorineural activity level; sterility assurance level; suction-assisted lipectomy
SDL serum digoxin level; speech discrimination level
SPL skin potential level; sound pressure level; splanchnic; spontaneous lesion; staphylococcal phage lys...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HCP Hearing Conservation Program
HHIE Hearing Handicap Inventory for the Elderly
HI Hearing impairment
HL Hearing loss
NIHL Noise Induced Hearing Loss
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anterior palate vault level
    Àü±¸°³Á¤ ³ôÀÌ
  • antimicrobial level
    Ç×±ÕÁ¦Ä¡
  • blood alcohol level
    Ç÷Áß ¾ËÄÚ¿Ã ³óµµ
  • blood oxygenation level dependant
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • c-AMP level
    ȯ½Ä AMP ·¹º§
  • carinal level
    ºÐ±â ´ë
  • elevated transaminase level

    elevation (°Å»ó, »ó½Â, À¶±â, °íÀ§

    À§·Î ¿Ã¶ó°¨. ¾î´À ÇÑ ºÎºÐÀÌ ³ôÀÌ ¼Ú¾Æ ¿À¸§. µé¾î¿Ã¸° ºÎÀ§, ¶Ç´Â Á»´õ ³ôÀº Á¡.
  • fasting blood sugar level
    °øº¹ ½Ã Ç÷´çÄ¡
  • level
    ¼öÁØ, ±íÀÌ, Ä¡, ´ÜÀ§, Ãþ, À§, ³ôÀÌ, ¹üÀ§, ¼öÁرâ, ÁØÀ§
  • maximal expiratory level
    ÃÖ´ë È£±âÀ§
  • maximal inspiratory level
    ÃÖ´ë Èí±âÀ§
  • mucosal level
    Á¡¸· ¼öÁØ
  • permissible radiation exposure level
    »ç¼± ³ëÃâ Çã¿ë·®
  • subconscious level
    ÀáÀç ÀÇ½Ä ¼öÁØ
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
hearing loss, noise-induced Hearing loss from exposure to noise. The loss is often in the frequency range 4000-6000 hertz.
(12 Dec 1998)
hearing loss, partial A condition in which the sense of hearing, although defective, is functional with or without a hearing aid. The hearing level for speech is approximately 40-70 decibels I.s.o. (international organization for standardization) or 30-60 db a.s.a. (american standards association).
(12 Dec 1998)
hearing loss, sensorineural Hearing loss resulting from damage to the sensory mechanism internal from the oval and round windows.
(12 Dec 1998)
Helmholtz theory of hearing That the basilar membrane of the cochlea acts as a resonating structure, recording low tones from its apical turns and high tones from its basal turns.
Synonym: Helmholtz theory of hearing.
(05 Mar 2000)
sensorineural hearing loss <neurology> A form of deafness that occurs due to dysfunction of the auditory nerve (cranial nerve VIII).
(27 Sep 1997)
normal hearing The ability to perceive sound normally.
Synonym: normal hearing.
Origin: G. Akousis, hearing
(05 Mar 2000)
organ of hearing The content of the cochlea including the portion of the membranous labyrinth containing the spiral organ (cochlear duct) and the perilymphatic channels (scalae) which lie on either side.
Synonym: labyrinthus cochlearis, organ of hearing.
(05 Mar 2000)
ACE level <investigation> This is a blood test which measures the concentration of angiotensin-converting enzyme (ACE) in the bloodstream.
Elevations in angiotensin-converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy.
The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
(15 Jan 1998)
acoustic reference level The biological reference level for sound measurements. When the term decibel is used to indicate the noise level, a reference quantity is implied; this reference value is usually expressed as a sound pressure of 20 micronewtons per square meter. The reference level is referred to as 0 decibels, the baseline of the scale of noise level's; this baseline is considered the weakest sound that can be heard by a person with very good hearing in an extremely quiet location. Other equivalent reference level's still being used include 0.0002 microbar and 0.0002 dyne per square centimeter.
(05 Mar 2000)
background level The average amount of a substance present in the environment. Originally referring to naturally occurring phenomena. Used in toxic substance monitoring.
(05 Dec 1998)
blood porphyrin level A test which is used to measure red blood cell porphyrin levels. Porphyrins are pigments found in both animal and plant life.
This test is useful in evaluating any number of porphyrin disorders (involving the various porphyrins) of red blood cells.
Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia.
Increased protoporphyrins may be seen in infection, thalassaemia, sideroblastic anaemia, iron deficient anaemia, increased erythropoiesis and lead poisoning. Increased uroporphyrins may indicate congenital erythropoietic porphyria or erythropoietic protoporphyria.
(27 Sep 1997)
carbon dioxide blood level A measure of the bicarbonate level in the blood based on a venipuncture specimen. The serum carbon dioxide is one of the normally reported values in the electrolytes profile. Lower levels of carbon dioxide indicate an acidosis. The normal level is 20 to 29 mEq/L. Lower than normal levels can indicate diabetic ketoacidosis, lactic acidosis, alcoholic ketoacidosis, kidney disease, renal failure, diarrhoea, Addison's disease, ethylene glycol poisoning or methanol poisoning. Greater than normal levels can be seen with excessive vomiting, hyperaldosteronism and Cushing's syndrome.
(27 Sep 1997)
vasopressin level This test measures the amount of ADH in the serum. It is used to detect disorders that may affect the level of ADH in the serum. Normal values are: 0 to 4.7 pg/ml. Elevated ADH levels can indicate a CNS infection, fluid imbalance, CNS tumour, SIADH or acute porphyria. Low levels can indicate: diabetes insipidus or damage to the pituitary gland.
(27 Sep 1997)
maximum permissible exposure level The highest level of exposure to a substance, usually noxious, in the environment or during diagnostic and therapeutic procedures, that a body can tolerate without injury.
(12 Dec 1998)
mean sea level <marine biology> A tidal datum: the arithmetic mean of hourly water elevations observed over a specific 19-year cycle. Points on land can be referenced to a mean sea level, in which case the datum assumes zero elevation.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mean sea level
    Æò±Õ ÇØ¸é(ÇØ¹ß ±âÁØ)
  • ordinary level
    G;C;E;ÀÇ ±âÃÊ Çз ½ÃÇè
  • replacement level
    Àα¸ º¸Ãæ ¼öÁØ(ÃÑÀα¸¸¦ À¯ÁöÇÏ´Â µ¥¿¡ ÇÊ¿äÇÑ Ãâ»ý·ü)
  • resistance level
    (½Ã¼¼ÀÇ)ÀúÇ×¼±(½Ã¼¼°¡ ÁÁ±â ¶§¹®¿¡ ÆÇ¸Å°¡ Ȱ¹ßÇØÁ®,±× ÀÌ»óÀÇ ½Ã¼¼ »ó½ÂÀÌ µÐÇØÁö´Â °¡°Ý ¼öÁØ)
  • sea level
    ÇØ¸é
  • spirit level
    ÁÖÁ¤ ¼öÁرâ
  • water level
    ¼öÆò¸é
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á